ICH Q10: Pharmaceutical Quality System

ICH Q10 (Pharmaceutical Quality System)

ICH Q10 (Pharmaceutical Quality System) is the ICH Quality-series guideline that defines a model pharmaceutical quality system (PQS) spanning a product's entire life cycle -- pharmaceutical development, technology transfer, commercial manufacturing, and product discontinuation. A quality system meets ICH Q10 when it (1) sits on top of applicable Good Manufacturing Practice (GMP/ICH Q7) requirements and incorporates ISO 9001 quality-management-system principles, (2) applies the risk-based tools of ICH Q9 (Quality Risk Management) to prioritize and scope quality decisions, (3) uses the science- and risk-based product/process understanding built during development under ICH Q8 (Pharmaceutical Development), and (4) operates four specific management enablers -- a Process Performance and Product Quality Monitoring System, a Corrective and Preventive Action (CAPA) system, a Change Management System, and Management Review -- under documented senior-management responsibility and a stated commitment to continual improvement.

ByCASRAI Editorial Board

· Last updated 18 Jul 2026

Ask about ICH Q10 (Pharmaceutical Quality System)

Answers are drawn from this dictionary entry and the rest of the CASRAI corpus, with a link to every source.

Answers are AI-generated from CASRAI’s own published pages and can be wrong, so check the linked sources before relying on one; your question is logged without personal data — never sold, never used to train a third-party model — to show us what CASRAI is missing, so please do not type personal or confidential details. How we use this

Worked examples

Is an instance

A drug product manufacturer maintains a Process Performance and Product Quality Monitoring System that trends in-process and release test results across every commercial batch; when a control-chart signal flags an emerging shift in a critical quality attribute, the deviation feeds the CAPA system, the root-cause investigation and corrective action are documented, and the outcome is reported up through a scheduled management review -- the full ICH Q10 monitor/act/review cycle operating on top of the site's existing GMP program.

Is an instance

A sponsor transferring a manufacturing process from a development site to a commercial contract manufacturing organization (CMO) uses a documented technology-transfer protocol, drawing on the process understanding and control strategy established under ICH Q8 and the risk assessment performed under ICH Q9, to define which process parameters and quality attributes must be verified at the receiving site before the transfer is considered complete -- an ICH Q10 life-cycle-stage transfer, distinct from routine commercial-phase monitoring.

Looks similar, but isn't

Not an instance

A site treats its quality manual as a static compliance document written once for an inspection and never revisited, with no defined management-review cadence and no mechanism for CAPA findings to actually change a procedure. ICH Q10 explicitly requires senior management to review the PQS's performance and drive continual improvement -- a quality system that only documents that GMP was followed, without a working feedback loop back into process and product understanding, is not operating as an ICH Q10 pharmaceutical quality system even if the site is otherwise GMP-compliant.

ICH Q10 is the International Council for Harmonisation (ICH) Quality-series guideline titled “Pharmaceutical Quality System,” reaching ICH Step 4 (final adoption by the ICH Assembly) in June 2008. It does not replace ICH Q7 Good Manufacturing Practice or regional GMP regulations; instead, it sits on top of them, defining a comprehensive, life-cycle-spanning quality-management model that regulators expect a modern pharmaceutical quality system to operate as, not merely comply with.

Scope: the full product life cycle

ICH Q10 applies to drug substances and drug products, including biotechnology and biological products, across four life-cycle stages: pharmaceutical development, technology transfer, commercial manufacturing, and product discontinuation. The guideline is explicit that its elements should be applied in a manner proportionate to each stage — a development-phase quality system does not need the same level of formality as a commercial-manufacturing one, but the underlying PQS model is meant to carry through all four stages rather than being rebuilt at each one.

How Q10 relates to Q8 and Q9

ICH Q10 is best understood as the third leg of a deliberately interlocking set of ICH Quality guidelines:

ICH Q8 (Pharmaceutical Development) establishes how product and process understanding is built during development, including the concepts of a design space and quality by design (QbD).
ICH Q9 (Quality Risk Management) supplies the systematic risk-assessment, risk-control, risk-communication, and risk-review process used to make and document quality decisions.
ICH Q10 provides the management-system framework — the organizational structure, responsibilities, and enablers — within which the product/process knowledge from Q8 and the risk-based judgment from Q9 actually get applied, tracked, and improved over the product’s commercial life.

Regulatory and industry guidance commonly refers to Q8, Q9, and Q10 together as a triad because none of the three is designed to be implemented in isolation: Q10’s monitoring and CAPA systems need Q9’s risk-based prioritization to decide what to monitor most closely, and both draw on the process knowledge that Q8 requires be established and documented during development.

The four PQS enablers

ICH Q10 organizes ongoing quality-system operation around four linked enablers, sitting above existing GMP requirements:

Process Performance and Product Quality Monitoring System — ongoing trending of in-process and release data against defined quality attributes, to detect variation before it becomes an out-of-specification result.
Corrective and Preventive Action (CAPA) System — structured investigation of deviations and quality signals, with documented root-cause analysis and follow-through on effectiveness.
Change Management System — formal evaluation of proposed changes to process, equipment, or documentation for their quality-attribute impact before implementation, rather than ad hoc revision.
Management Review of Process Performance and Product Quality — periodic senior-management review of PQS outputs (monitoring trends, CAPA status, change history, audit/inspection findings) that closes the loop and drives the guideline’s stated commitment to continual improvement.

ICH Q10 also assigns explicit management responsibilities — a quality policy, resource allocation, and an internal communication process — that go beyond what regional GMP regulations typically specify in that much organizational detail, which is part of why regulators treat a genuine ICH Q10 implementation as a higher bar than baseline GMP compliance alone.

Relationship to ISO 9001

ICH Q10 was deliberately built to be compatible with the international ISO 9001 quality-management-system standard, borrowing its general quality-management-system architecture (management responsibility, resource management, process realization, measurement/analysis/improvement) while adding the pharmaceutical-specific GMP and life-cycle content ISO 9001 does not itself cover. A site with an existing ISO 9001 system is not automatically ICH Q10-compliant, but the two are structured to overlay rather than conflict.

Where Q10 fits in the ICH Quality series

ICH Q10 is one guideline within the broader ICH Q/S/E/M guideline taxonomy — the Quality (Q) category also includes stability testing (ICH Q1) and API manufacturing GMP (ICH Q7). Sponsors and CDMOs typically reference Q10 alongside Chemistry, Manufacturing, and Controls (CMC) documentation and Continued Process Verification (CPV) programs, both of which operationalize parts of the Q10 monitoring enabler during commercial manufacturing.

Related terms

Use in your systems

JATS XML <role> element

xml

<role vocab="credit"
      vocab-identifier="https://casrai.org/dictionary/"
      vocab-term="ICH Q10 (Pharmaceutical Quality System)"
      vocab-term-identifier="https://casrai.org/dictionary/term/ich-q10-pharmaceutical-quality-system" />

Schema.org DefinedTerm (JSON-LD)

json

{
  "@context": "https://schema.org",
  "@type": "DefinedTerm",
  "@id": "https://casrai.org/dictionary/term/ich-q10-pharmaceutical-quality-system",
  "name": "ICH Q10 (Pharmaceutical Quality System)",
  "identifier": "https://casrai.org/dictionary/term/ich-q10-pharmaceutical-quality-system",
  "description": "ICH Q10 (Pharmaceutical Quality System) is the ICH Quality-series guideline that defines a model pharmaceutical quality system (PQS) spanning a product's entire life cycle -- pharmaceutical development, technology transfer, commercial manufacturing, and product discontinuation. A quality system meets ICH Q10 when it (1) sits on top of applicable Good Manufacturing Practice (GMP/ICH Q7) requirements and incorporates ISO 9001 quality-management-system principles, (2) applies the risk-based tools of ICH Q9 (Quality Risk Management) to prioritize and scope quality decisions, (3) uses the science- and risk-based product/process understanding built during development under ICH Q8 (Pharmaceutical Development), and (4) operates four specific management enablers -- a Process Performance and Product Quality Monitoring System, a Corrective and Preventive Action (CAPA) system, a Change Management System, and Management Review -- under documented senior-management responsibility and a stated commitment to continual improvement.",
  "inDefinedTermSet": "https://casrai.org/dictionary/domain/clinical-research#set",
  "url": "https://casrai.org/dictionary/term/ich-q10-pharmaceutical-quality-system",
  "sameAs": [],
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "publisher": {
    "@id": "https://casrai.org/#organization"
  },
  "dateModified": "2026-07-18T03:11:23",
  "inLanguage": "en"
}